The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the epac-1/Akt pathway

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 10, 2014, Pages 608-614

  Wu, X M ^a   Ou, Q Y ^a,b   Zhao, W ^a   Liu, J ^a   Zhang, H ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b HAINAN GENERAL HOSPITAL   (China)

Author keywords

apoptosis; cardiomyocytes; Epac 1; GLP 1 analog

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; EXCHANGE PROTEIN ACTIVATED BY CAMP 1; GLUCOSE; LIRAGLUTIDE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; EPAC-1 PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR EFFECT; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE SILENCING; GENETIC TRANSFECTION; GLUCOSE INTAKE; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOBLOTTING; INTERVENTION STUDY; INTRACELLULAR SIGNALING; MALE; MULTIPLE CYCLE TREATMENT; NEWBORN; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84909955874     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1384584     Document Type: Article

References (32)

1. Asghar O., Al-Sunni A., Khavandi K. et al. Diabetic cardiomyopathy. Clin Sci: 2009; 116 741 760
2. Lee Y., Gustafsson A. B. Role of apoptosis in cardiovascular disease. Apoptosis: 2009; 14 536 548
3. Narula J., Arbustini E., Chandrashekhar Y. et al. Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interrupt us and zombie myocytes. Cardiol Clin: 2001; 19 113 126
4. Baraka A., Abdel Gawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther: 2010; 15 175 181
5. Katare R. G., Caporali A., Oikawa A. et al. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolicdysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail: 2010; 3 294 305
6. Timmers L., Henriques J. P., de Kleijn D. P. et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol: 2009; 53 501 510
7. Noyan-Ashraf M. H., Momen M. A., Ban K. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes: 2009; 58 975 983
8. Bose A. K., Mocanu M. M., Carr R. D. et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes: 2005; 54 146 151
9. Sonne D. P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept: 2008; 146 243 249
10. Ban K., Kim K. H., Cho C. K. et al. glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology: 2010; 151 1520 1531
11. Matsubara M., Kanemoto S., Leshnower B. G. et al. Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res: 2011; 165 38 45
12. Bose A. K., Mocanu M. M., Carr R. D. et al. Myocardial Ischaemia-reperfusion injury is attenuated by intact Glucagon like Peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther: 2007; 21 253 256
13. Vyas A. K., Yang K. C., Woo D. et al. Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy. PLOS ONE: 2011; 6 e17178
14. Ravassa S., Zudaire A., Carr R. D. et al. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol: 2011; 300 H1361 H1372
15. Younce C. W., Burmeister M. A., Ayala J. E. Exendin-4 attenuated high glucoseinduced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol: 2013; 304 C508 C518
16. Bian Y. F., Wang D. X., Yang H. Y. et al. Glucagon like peptide-1 inhibits high glucose-induced injury of oxidative stress in cardiomyocytes of neonatal rats. Sheng Li Xue Bao: 2011; 63 387 395
17. Zhang L., ZHAO W., ZHANG Y. J. et al. Effects of glucagon-like peptide-1 receptor agonist on TGF-β1/Smad signaling pathway in myocardium of diabetic Rats. Chin J diabetes mellitus: 2013; 5 1 6
18. Yu Z., Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal: 2010; 22 1 8
19. Insel P. A., Zhang L., Murray F. et al. Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf): 2012; 204 277 287
20. Zhang B., Nweze I., Lakshmanan J. et al. Activation of a cyclic AMP-guanine exchange factor in hepatocytes decreases nitric oxide synthase expression. Shock: 2013; 39 70 76
21. Jang M. W., Yun S. P., Park J. H. et al. Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E(2) -induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. J Cell Physiol: 2012; 227 3756 3767
22. Watkins S. J., Borthwick G. M., Arthur H. M. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim: 2011; 47 125 131
23. Kuo W. W., Wang W. J., Tsai C. Y. et al. Diallyl trisufide (DATS) suppresses high glucose-induced cardiomyocyte apoptosis by inhibiting JNK/NFκB signaling via attenuating ROS generation. Int J Cardiol: 2013; 168 270 280
24. Mortuza R., Chakrabarti S. Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy. Heart Fail Rev: 2014; 19 75 86
25. Liu Q., Anderson C., Broyde A. et al. Glucagon-like peptide-1 and the exenatide analog AC3174improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol: 2010; 9 76
26. Ku H-C, Chen W-P, Su M-J. DPP4 Deficiency Exerts Protective Effect against H2O2Induced Oxidative Stress in Isolated Cardiomyocytes. PLOS ONE: 2013; 8 e54518
27. Chen T. H., Wo H. T., Wu C. C. et al. Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protect H9c2 cells from apoptosis. Immunopharmacol Immunotoxicol: 2012; 34 484 490
28. Kwak H. J., Park K. M., Choi H. E. et al. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal: 2008; 20 803 814
29. Suzuki S., Yokoyama U., Abe T. et al. Differential roles of Epac in regulating cell death in neuronal and myocardial cells. J Biol Chem: 2010; 285 24248 24259
30. Métrich M., Berthouze M., Morel E. et al. Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology. Pflugers Arch: 2010; 459 535 546
31. Misra U. K., Pizzo S. V. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem: 2012; 113 1488 1500
32. Tsai C. Y., Wang C. C., Lai T. Y. et al. Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes. Int J Cardiol: 2013; 30,168 1286 1297